ABSTRACT
@#<b>Objective</b> To study the setup error under deep inspiration breath hold (DIBH) guided by optical surface monitoring system (OSMS) and free breathing (FB) FB1 and FB2 (without OSMS guidance, directly set up the body marker line by laser lamp) in radiotherapy after radical mastectomy for left breast cancer, and to provide a basis for individualized clinical target volume-planning target volume (CTV-PTV) expansion for the doctor in charge to delineate the target volume. <b>Methods</b> A total of 36 patients with left breast cancer after radical mastectomy were selected and divided into three groups, in which cone beam computed tomography (CBCT) images were taken in three states: DIBH, FB1, and FB2, respectively. CBCT and CT images were analyzed for registration; the absolute error data of linear displacement in the ventro-dorsal, cranio-caudal, and left-right directions were recorded, and the expanding margin was calculated. <b>Results</b> The translation errors in the ventro-dorsal, cranio-caudal, and left-right directions were (0.06 ± 0.22) cm, (0.05 ± 0.23) cm, and (0.01 ± 0.24) cm in the DIBH group, (0.07 ± 0.21) cm, (0.02 ± 0.23) cm, and (0.02 ± 0.21) cm in the FB1 group, and (0.07 ± 0.24) cm, (0.07 ± 0.34) cm, and (0.25 ± 0.09) cm in the FB2 group. The statistical results of the DIBH group and FB1 group in the ventro-dorsal, RTN, and ROLL directions were significantly different (<i>P</i> < 0.05). The statistical results of the FB1 group and FB2 group in the ventro-dorsal direction were significantly different. The relation of three groups in the value of margin of planning target volume was DIBH < FB1 < FB2 in the ventro-dorsal and cranio-caudal directions and FB1 < DIBH < FB2 in the left-right direction. <b>Conclusion</b> OSMS-guided DIBH radiotherapy in patients with left breast cancer after radical mastectomy can reduce the setup error and provide an important basis for individualized CTV-PTV expansion for the doctor in charge to delineate the target volume.
ABSTRACT
ObjectiveTo assess the efficacy of intrahepatic arterial infusion of Endostar (rh-endostatin, YH-16) combined with transcatheter arterial chemoembolization (TACE) for the treatment of advanced hepatocellular carcinoma (aHCC). MethodsThe study enrolled 76 aHCC patients who were admitted to and treated at the Petroleum Hospital Affiliated to Tianjin Medical University during September 2009 to June 2011. Of these, 44 patients were treated with TACE plus Endostar, and the other 32 (the control group) with TACE alone. After treatment, all patients were subjected to non-scheduled re-examination by computed tomography (or magnetic resonance imaging), in order to check tumor recurrence (or metastasis) and angiogenesis. Count data were compared between groups using the χ2 test. Survival curves were plotted using the Kaplan-Meier method, and postoperative survival differences were analyzed using the log-rank test. ResultsCompared with the control group, the experimental group treated with TACE plus Endostar had significantly increased response rate (7045% vs. 43.75%, χ2=5.47, P＜0.05) and disease control rate (84.09% vs. 56.25%, χ2=7.18, P＜0.01). The median progression-free survival significantly differed between groups (9.00 vs. 5.00 months , P=0.044), whereas the median overall survival showed no significant difference (10.64 vs. 8.11 months, P=0.448). ConclusionTACE plus Endostar significantly improves the short-term outcome and progression-free survival but has little effect on the overall survival span in patients with aHCC.